Michael C Brown

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4290314/publications.pdf

Version: 2024-02-01

38 papers	1,115 citations	430843 18 h-index	414395 32 g-index
40 all docs	40 docs citations	40 times ranked	1550 citing authors

#	Article	IF	Citations
1	Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigenâ€“specific CTLs. Science Translational Medicine, 2017, 9, .	12.4	180
2	Antiâ€“LAMP-2 Antibodies Are Not Prevalent in Patients With Antineutrophil Cytoplasmic Autoantibody Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2012, 23, 545-555.	6.1	115
3	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nature Communications, 2021, 12, 352.	12.8	77
4	Oncolytic polio virotherapy of cancer. Cancer, 2014, 120, 3277-3286.	4.1	67
5	MNK Controls mTORC1:Substrate Association through Regulation of TELO2 Binding with mTORC1. Cell Reports, 2017, 18, 1444-1457.	6.4	55
6	Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget, 2016, 7, 79828-79841.	1.8	53
7	T cells down-regulate macrophage TNF production by IRAK1-mediated IL-10 expression and control innate hyperinflammation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5295-5300.	7.1	49
8	Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nature Communications, 2021, 12, 1858.	12.8	47
9	Induction of Viral, 7-Methyl-Guanosine Cap-Independent Translation and Oncolysis by Mitogen-Activated Protein Kinase-Interacting Kinase-Mediated Effects on the Serine/Arginine-Rich Protein Kinase. Journal of Virology, 2014, 88, 13135-13148.	3.4	45
10	XIAP Regulation by MNK Links MAPK and NFÎºB Signaling to Determine an Aggressive Breast Cancer Phenotype. Cancer Research, 2018, 78, 1726-1738.	0.9	45
11	Mitogen-Activated Protein Kinase-Interacting Kinase Regulates mTOR/AKT Signaling and Controls the Serine/Arginine-Rich Protein Kinase-Responsive Type 1 Internal Ribosome Entry Site-Mediated Translation and Viral Oncolysis. Journal of Virology, 2014, 88, 13149-13160.	3.4	40
12	Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. Current Opinion in Virology, 2015, 13, 81-85.	5.4	40
13	Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. Journal of Neuropathology and Experimental Neurology, 2018, 77, 696-702.	1.7	38
14	Mitotic Phosphorylation of Eukaryotic Initiation Factor 4G1 (eIF4G1) at Ser1232 by Cdk1:Cyclin B Inhibits eIF4A Helicase Complex Binding with RNA. Molecular and Cellular Biology, 2014, 34, 439-451.	2.3	35
15	Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. Journal of Virology, 2018, 92, .	3.4	35
16	Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nature Communications, 2020, 11, 524.	12.8	29
17	Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. Cancer Cell, 2022, 40, 439-440.	16.8	27
18	The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. Journal of Surgical Research, 2019, 236, 209-215.	1.6	24

#	Article	IF	Citations
19	Regulation of Hypoxia-Inducible Factor 1Î± during Hypoxia by DAP5-Induced Translation of PHD2. Molecular and Cellular Biology, 2018, 38, .	2.3	18
20	Enterovirus 2A ^{pro} Cleavage of the YTHDF m ⁶ A Readers Implicates YTHDF3 as a Mediator of Type I Interferon-Driven JAK/STAT Signaling. MBio, 2021, 12, .	4.1	18
21	Aryl Hydrocarbon Receptor Signaling Controls CD155 Expression on Macrophages and Mediates Tumor Immunosuppression. Journal of Immunology, 2021, 206, 1385-1394.	0.8	15
22	Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by â€˜autoantigen complementarityâ€™. Journal of Autoimmunity, 2015, 59, 8-18.	6.5	14
23	MNK inversely regulates TELO2 vs. DEPTOR to control mTORC1 signaling. Molecular and Cellular Oncology, 2017, 4, e1306010.	0.7	12
24	Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus. Discovery Medicine, 2015, 19, 359-65.	0.5	10
25	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. Neuro-Oncology, 2019, 21, vi7-vi7.	1.2	5
26	Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.. Journal of Clinical Oncology, 2018, 36, e12641-e12641.	1.6	5
27	Low tumor mutational burden and immunotherapy in gliomas. Trends in Cancer, 2022, 8, 345-346.	7.4	5
28	PKR Binds Enterovirus IRESs, Displaces Host Translation Factors, and Impairs Viral Translation to Enable Innate Antiviral Signaling. MBio, 0, , .	4.1	4
29	Harnessing virus tropism for dendritic cells for vaccine design. Current Opinion in Virology, 2020, 44, 73-80.	5.4	3
30	IMMU-31. DYSFUNCTIONAL STING PATHWAY SIGNALING COMPROMISES INNATE IMMUNITY IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi127-vi128.	1.2	1
31	IMMU-34. ATRX MUTATIONS PREDICT RESPONSE TO INNATE BASED THERAPY IN GLIOMA. Neuro-Oncology, 2019, 21, vi126-vi126.	1.2	1
32	Safety and efficacy of murine PVSRIPO plus anti-PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model.. Journal of Clinical Oncology, 2021, 39, 2560-2560.	1.6	1
33	Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity. Cancer Treatment and Research, 2022, 183, 91-129.	0.5	1
34	EXTH-51. GENETICALLY STABLE POLIOVIRUS VECTOR PLATFORM FOR DIPG IMMUNOTHERAPY. Neuro-Oncology, 2019, 21, vi93-vi93.	1.2	0
35	OTME-16. Polio virotherapy of murine brain tumors causes microglia/macrophage proliferation and inflammation that is potentiated by immune checkpoint blockade. Neuro-Oncology Advances, 2021, 3, ii17-ii17.	0.7	0
36	EPCO-21. STING PROMOTER EPIGENETIC SILENCING IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii73-ii73.	1.2	0

#	Article	IF	Citations
37	IMMU-18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN GLIOMAS. Neuro-Oncology, 2020, 22, ii108-ii108.	1.2	0
38	TMOD-17. ONCOLYTIC POLIOVIRUS AS A PROBE FOR MECHANISMS OF IMMUNE RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii231-ii231.	1.2	0